NovMetaPharma Co., Ltd. (XKON:229500)
South Korea · Delayed Price · Currency is KRW 9,980.00
-420.00 (-4.04%)
At close: Apr 16, 2026
NovMetaPharma Market Cap
NovMetaPharma has a market cap or net worth of 128.16 billion as of April 16, 2026. Its market cap has increased by 85.15% in one year.
Market Cap
128.16B
Enterprise Value
n/a
Revenue
1.30B
Ranking
n/a
PE Ratio
83.17
Stock Price
9,980.00
Market Cap Chart
Since April 5, 2017, NovMetaPharma's market cap has increased from 74.59B to 128.16B, an increase of 71.81%. That is a compound annual growth rate of 6.17%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 128.16B | -21.71% |
| Dec 30, 2025 | 163.69B | 187.16% |
| Dec 30, 2024 | 57.00B | -46.33% |
| Dec 29, 2022 | 106.21B | -45.89% |
| Dec 30, 2021 | 196.29B | -9.50% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Apr 5, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ISU Abxis | 196.91B |
| Ensol Biosciences | 190.06B |
| Prestige Biologics | 178.83B |
| QuadMedicine | 153.17B |
| BIO-FD&C | 125.48B |
| CORESTEMCHEMON | 113.12B |
| ViGenCell | 111.52B |
| KoBioLabs | 109.52B |